us-fda-guidance-3df6768872f38e9a08cf3663d69046eb•Study and Evaluation of Sex Differences in the Clinical Evaluation of Drugs: Guidance for Industry
Study and Evaluation of Sex Differences in the Clinical Evaluation of Drugs: Guidance for Industry
us-fda-guidance-3df6768872f38e9a08cf3663d69046ebStudy and Evaluation of Sex Differences in the Clinical Evaluation of Drugs: Guidance for IndustryGuidance
Administrative guidance, not enacted legislation. This captured publisher edition preserves the listed document and attachments; later developments are not independently consolidated.
- Docket Number:
- FDA-1993-D-0184
- Issued by:
- Guidance Issuing OfficeCenter for Drug Evaluation and Research
The FDA published Good Guidance Practices in February 1997. This guidance was developed and issued prior to that date.
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-1993-D-0184.
Continue your research in ChatGPT or Claude
Connect Omnilex to search the legal corpus from your AI assistant.